Background: Cystic fibrosis (CF) is the most common lethal recessive disease affecting children in the U.S. and Europe. For this reason, a number of ongoing attempts are being made to treat the disease either by gene therapy or pharmacotherapy. Several phase 1 gene therapy trials have been completed, and a phase 2 clinical trial with the xanthine drug CPX is in progress. The protein coded by the principal CFTR mutation, AF508-CFTR, fails to traffic efficiently from the endoplasmic reticulum to the plasma membrane, and is the pathogenic basis for the missing cAMP-activated plasma membrane chloride
Introduction
Pharmacogenomics of genetic diseases is a relatively unexplored but promising field, in which the genetic consequences of effective gene or drug therapy can potentially be assessed at the cellular level in terms of specific patterns of global gene expression (1, 2) . It is hoped that such patterns could be employed as biologically relevant surrogate endpoints when searching for more effective drugs or genes (3) . Cystic fibrosis (CF), the most common lethal autosomal recessive disease affecting the U.S. and European populations (4) , is an attractive target for pharmacogenomic studies. It is one of the first diseases for which gene therapy has been attempted (5, 6) and various drug therapies are currently being developed (7, 8) . CF is most frequently associated with a homozygous AF508 mutation in the CFTR gene (9) (10) (11) , and a single copy of the mutant gene is carried by approximately 5% of the population (12, 13) .
Among the several potential CF drugs being studied (14) , the xanthine drug CPX is presently in phase II clinical trials in CF patients. For that reason, we have focussed our attention in the present paper specifically on CPX. The rationale for administration of CPX to CF patients has been severalfold. First, the drug activates wild-type and mutant AF508-CFTR channels in cells (15) (16) (17) (18) (19) (20) and planar lipid bilayers (21) . In addition, CPX also promotes correction of the intrinsic trafficking defect of the AF508-CFTR molecule in the endoplasmic reticulum (8) . The mutant CFTR is misfolded (22) , and it has been hypothesized that the interaction of the misfolded protein with CPX results in corrected folding and proper trafficking to the plasma membrane (8, 23) . However, CFTR is known to interact with numerous other cellular proteins (24) (25) (26) , and CPX also interacts with classical adenosine receptors (27) . It is thus possible that CPX may affect CFTR trafficking and function by additional actions that are not immediately apparent from the simpler in vitro and in vivo experiments. Furthermore, different CFTR mutations have profoundly different disease phenotypes (28) , including a propensity to develop gastrointestinal and other cancers (29) (30) (31) (32) (33) (34) (35) (36) . We have therefore hypothesized that the gene expression patterns of human epithelial cells expressing mutant or wild-type CFTR might differ, and that a drug such as CPX might convert the mutant gene expression pattern into one more characteristic of wild-type CFTR.
To test this hypothesis, we have turned to genomic techniques permitting disease-dependent global quantitative analysis of gene expression (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) . The data presented here clearly demonstrate that the expression of either wildtype or AF508-CFTR in cells has both common as well as specific differential consequences for global gene expression. We have used these data to identify not only the specific consequences of expressing either wild-type or AF508-CFTR in cells, but also the global genomic consequences of gene transfer, as would occur as a consequence of "gene therapy." In addition, we have identified differential effects of CPX on global gene expression, depending on whether wildtype or mutant CFTR is being expressed. Most importantly, CPX labeled cDNA probes were synthesized from 1 ,ug of poly A+ RNA from each sample using MMLV reverse transcriptase, dNTP mix, and the cDNA synthesis (CDS) primer mix comprising the oligonucleotide sequences for the 588 genes spotted on the human Atlasg cDNA array (Clonetech, Carlsbad, CA). The reaction was carried out in a thermocycler set at 500C for 25 min and terminated by the addition of 0.1 M EDTA, pH 8.0, and 1 mg/ml glycogen. The 32P-labeled cDNA probes were purified from unincorporated 32P-labeled nucleotides by using a CHROMA column (Clonetech, Palo Alto, CA), as recommended by the manufacturer. The human Atlas cDNA expression array was prehybridized using Express Hyb (Clonetech) at 68°C for 1 hr and hybridized overnight at 680C with the denatured and neutralized 32P-labeled cDNA probes.
The membrane was washed three times with 2 x sodium chloride and sodium citrate (SSC), 1% SDS at 680C for 30 min each, and twice with 0.1% SSC, 0.5% SDS at 680C for 30 min each. The Atlas array was then exposed overnight to X-ray film or for 6 hr to a Storm PhosphorImager (Molecular Dynamics, Sunnyvale, CA) plate. All data shown here were derived solely from the first use of each microarray blot.
IMAGING AND QUANTITATION OF THE cDNA ARRAY.
Atlas cDNA array blots were assayed on a Storm Phosphorlmager using proprietary PhosphorImager screens. Each blot was exposed for 6 hr. The intensity of each grid point, at a resolution of 200 ,um, was quantified, including the ubiquitin standard and the blanks. The intensity data were then loaded into a Microsoft Excell spreadsheet. To determine the absolute density, each grid point was corrected by subtraction of the background and divided by the intensity of the ubiq- Fig. 2a for an example). For each graph, we calculate the averages and the standard deviations of the distribution of the logarithms of the individually measured gene expression ratios on the horizontal and vertical axes. We also perform this calculation for the differences between the logs of each pair of ratios of all genes (see Figs. 2b-d for examples). The criterion of being more than 1 standard deviation (1 SD) away from the respective average is chosen as an index of those genes in parental cells whose expression levels had been changed by the transfection of either wild-type or AF508-CFTR. We use a 2 SD criterion for determining that a change is significant. The SD values are calculated separately for expression ratios between wild-type or mutant cells relative to parental cells, or for differences in expression level ratios between wild-type and mutant cells. Using the SD as a discriminator in this way is one of several novel contributions of the GRASP approach to mining gene expression data. Note that the genes whose relative expression levels occur on the diagonal are those genes whose expression levels are mutation independent, or are simply related to transfection, per se.
The second step in the GRASP data mining approach is to represent the effects of drugs or genes as a vector in genomic space. We define here a genomic vector as originating on the location specified by the gene's expression levels in the absence of drug, and terminating at the location specified by the gene's expression levels in the presence of the drug. The length of this genomic vector is a measure of the efficacy of the drug's effect on the expression of that particular gene. The angle is related to the differential effect of the drug depending on the mutational state of CFTR. For example, the vectors of those genes for which the effects of CPX on their expression level are not specifically dependent on the CFTR mutation state have angles close to the main diagonal (i.e., -45°in the positive direction or -2250 in the negative direction). Conversely, the vectors for the genes whose expression is significantly dependent on the mutational status of CFTR are sorted to the 2nd quadrant (90 ' 0 c 1800) or to the 4th quadrant (270
Vector lengths can be discriminated by their number of SDs from the average length (see Fig. 4 for an application). We Figure 2a , in which ratios of expression levels of all 588 mRNAs are plotted using respective data from all three cell types. In the figure, the horizontal axis is the ratio of expression levels of given genes in wild-type CFTR-transfected cells relative to parental cells alone. The vertical axis in this figure is the ratio of expression of the same genes in AF508-CFTR-transfected cells relative to parental cells alone. As described in Materials and Methods, SDs have been calculated from the distributions of ratios of gene expression. Histograms of these ratios are explicitly shown for wild-type CFTR relative to parental cells (Fig. 2b ), AF508-CFTR relative to parental cells (Fig. 2c) , and AF508-CFTR relative to wildtype CFTR cells (Fig. 2d) .
The first step in this data-sieving operation is to eliminate all genes whose expression ratios differ from 1.0 by < 1 SD in both transfected cells. Table 1 ). The classes of differences among these remaining 26 cDNA microarrays were prepared (Fig. 3a,b) Logically, a set of such genomic markers might be useful in predicting whether a specific drug might be of therapeutic use; conversely, the possibility of unwanted side effects might also be discerned. To test this hypothesis, our strategy has been to view graphs such as that shown in Figure 2a as "genomic space," before and after CPX treatment, respectively. This allows the construction of a drug-related "difference vector" between the location of the data point in the absence of CPX and the location in the presence of CPX (see Materials and Methods for more details). A low-resolution radial histogram of the angular distribution of these difference vectors is shown in Figure 4a . The labels on the circumference of the circle represent the angles of the vectors from the horizontal axis. The radius of the circle represents the numbers of genes at that angle. The given angle is that direction in genomic space (see Fig. 2 Fig. 4c , blue line). The latter vectors represent the noise in the system. By contrast, the higher-resolution histograms (see Fig. 4b,c) show smaller numbers of vectors whose angles fall into the 2nd quadrant (90 ' 0 -1800) or the 4th quadrant (270 < 0 < 0°). The importance of a gene vector being sorted into the 2nd or 4th quadrant is that these are the genes whose response to CPX is mutation dependent. The distribution of vectors of average length (i.e., those that are within 1 SD of the logarithmic mean) are colored cyan in the histogram, and show a significant population in the 2nd and 4th quadrants. This population consists of 69 genes (12%). As an alternative to simply listing all 69, we have selected a subset of these genes (see Table 3 ) that have been shown above to be changed significantly (.2 SDs) by either mutation or CPX.
As shown in Table 3 , the advantage of data mining using drug vector analysis is that the vector angle allows us to distinguish between CPX effects that are either predominantly on mutant cells, predominantly on wild-type cells, or on both mutant and wild-type cells but in opposite directions. As an example of the latter situation in the 2nd quadrant, changes in the 1200-1500 range delineate genes (e.g., BRCA2) in which CPX exposure leads to an expression increment in mutant CFTR cells but a (53) (54) (55) . Therefore, discerning whether these CPX-dependent effects are therapeutically wanted or unwanted in terms of repair of specific CFTR functions will require much further study.
Another interesting aspect of these results is that of those genes shown by our present work to be significantly changed by CFTR mutation or by CPX, surprisingly few have been historically associated with CF. The Atlas microarray is far from complete with regard to CF. However, it does contain at least 25 genes that have been thought at one time or another to be associated with CF, and we thought it would be of interest to summarize the data for them in Table 4 . Indeed, most of these genes are not affected by the mutation, except for HSP70, which is reduced, and mucl8 (a mucin) and ILIO, which are increased. By contrast, in the presence of CPX, many of these genes are increased. The most profound among these include PKA regulatory subunits; the tyrosine kinase JAKI; AXL tyrosine kinase; a panepithelial glycoprotein; HSP60, HSP70, and HSP86; MUC 18; caspase9; IL6; and, marginally, the Al-adenosine receptor. Presumably, with further study of larger arrays and under different conditions, it will be possible to identify a more complete set of CF-relevant reporter genes, and to construct a CF chip or blot suitable for CF drug discovery. Since we are presently analyzing only 588 of the 100,000 potential genes in the human genome, we can extrapolate by proportion that there could be as many as 5000 CF-relevant genes.
One advantage of the GRASP approach to accurate data seiving is that the intrinsic high number of genes in each blot can be employed in concert to profoundly raise the statistical strength of the analysis. On the basis of our own analysis of the ATLAS system in this series of experiments (see Materials and Methods for statistics), data from individual cDNA targets could just as easily been used. However, the problem with this simple approach is that the number of genes that are observed to change expression in a mutation-or drug-dependent manner becomes very large. Then, to determine whether a specific change, no matter how large or small, is truly significant, a large number of experiments must be performed. Given the current cost of an individual blot, this ceases to be a viable option. However, by asking, instead, whether any specific change is greater than the SD calculated for the entire sample, we take into account the entire sample when deciding on the significance of the specific change. This is the basis of the GRASP genome seiving technique.
There is also an additional advantage to presenting the expression data as a ratio to the same gene expressed in the parental cell line. The parental cell line in the denominator is genetically very similar to the cells in the numerator, except for the transfected CFTR gene. The parental cell thereby provides a biologically relevant normalization factor. We might point out here that such a specific comparison is intrinsically difficult to 
